WTA Introduces Genetic Testing Requirement for Players

The Women's Tennis Association (WTA) has announced a new requirement for all players to undergo genetic sex testing to compete on the WTA Tour. This policy, which is part of the updated women's eligibility guidelines, will take effect shortly.

Under the new rules, players must provide a sample—either a cheek swab, blood, or saliva—to test for the SRY gene, associated with male characteristics. A negative result, indicating the absence of this gene, will be necessary for players to participate in the Tour.

Players will only need to be tested once in their lifetime. However, those who test positive for the SRY gene will undergo additional medical evaluations before being allowed to compete. Additionally, players must sign a document acknowledging that refusal to participate in testing could lead to disciplinary measures.

This policy marks a shift from the WTA's previous stance, which permitted transgender women to compete if their testosterone levels were maintained below a certain threshold for two years. Currently, there are no known transgender women competing on the WTA Tour.

The WTA emphasized that the women's eligibility policy aims to ensure equitable opportunities in women's professional tennis and uphold fair competition. The governing body has committed to handling this sensitive issue with respect and dignity for all players.

This move aligns with similar regulations introduced in other sports, such as World Athletics and World Boxing, which have also implemented genetic testing requirements for female category competitors.